Tandem Diabetes (TNDM) Prelim. Q4 Revenue Beats
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Tandem Diabetes Care Announces Preliminary 2017 Results and Provides 2018 Guidance
January 9, 2018 4:15 PM ESTGuidance for 2018 Reflects Expectation of Continued Growth
SAN DIEGO--(BUSINESS WIRE)-- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported select, unaudited and preliminary results for the year and quarter ended December 31, 2017.
In comparing the fourth quarter of 2017 to the same period of 2016:
GAAP sales increased to approximately $39 million to $40 million from $28.9 million Non-GAAP sales increased to approximately $39 million to $40 million from $24.8 million Pump shipments increased to... More